Under construction – not a live service

Skip to content

Frontlight Research

Institution

Centre Hospitalier Universitaire de Nice

Nice, FranceWebsite

Also known as: CHU de Nice

453running trials
185closed trials
14,312publications (OpenAlex)

Running trials

Not yet recruiting
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis
NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source
Not yet recruiting
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· Phase 3· Bristol-Myers Squibb· Source
Not yet recruiting
Analysis of histological risk factors and biomarkers in paediatric retinoblastoma
2024-515962-15-00· Phase 2· Institut Curie· Source
Not yet recruiting
Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas
NCT07924384· Institut Curie· Source
Not yet recruiting
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source
Not yet recruiting
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source
Not yet recruiting
Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose
NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· Phase 2· Hoffmann-La Roche· Source
Not yet recruiting
A study in young people and adults to learn about the medicine ritlecitinib for treatment of patchy hair loss, known by the medical term as moderate alopecia areata
2026-526355-62-00· Phase 3· Pfizer Inc.· Source
Not yet recruiting
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic Leukemia
NCT07852494· Centre Hospitalier Universitaire de Nice· Source
Not yet recruiting
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
NCT07818356· Phase 4· University Hospital, Toulouse· Source
Recruiting
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Not yet recruiting
Evaluate the superiority of Treatment with RAvulizumab vs plasma exchange during the first episode or a relapse In acute neuromyelitis optica (NMO) patients: a national, multicentric, randomised trial
2026-526632-39-00· Phase 3· Les Hopitaux Universitaires De Strasbourg· Source
Not yet recruiting
Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity
NCT07903025· Axomove· Source
Recruiting
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
NCT07843498· Phase 3· Hoffmann-La Roche· Source
Recruiting
Comparison of Arterial and Capillary Blood Gas Analyses in Patients With Respiratory Distress Due to COPD or APE
NCT07835945· Centre Hospitalier Universitaire de Nice· Source
Recruiting
Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments
NCT07501507· Phase 2/3· Centre Hospitalier Universitaire de Nice· Source
Recruiting
Evaluating Aganirsen Eye Drops to Reduce the Number of Aflibercept Injections in Wet Age-Related Macular Degeneration Patients.
2026-526775-27-00· Phase 2· Laboratoires Kol· Source
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289· Phase 3· UCB Biopharma SRL· Source
Not yet recruiting
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
NCT07719348· Phase 1/2· Servier· Source
Recruiting
Feasibility of the Application of a new Six-month Treatment for multidrug-resistant tuberculosis (MDR-TB) patients in France (FAST-MDR)
2024-512763-32-00· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
2025-525016-41-00· Phase 2· AstraZeneca AB· Source
Not yet recruiting
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
NCT07721363· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Not yet recruiting
Topical Clobetasol Propionate for Inflammatory Hand Osteoarthritis
NCT07812701· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Not yet recruiting
Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial
2025-521493-33-00· Phase 3· Centre Hospitalier Intercommunal Creteil· Source
Not yet recruiting
OBINUSS - A trial to evaluate a new drug in systemic sclerosis: obinutuzumab.
2025-524003-68-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· Phase 3· Charite University, Berlin, Germany· Source
Not yet recruiting
Mitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy and Nb-UVB for Treating Vitiligo
NCT07557693· Phase 2/3· Centre Hospitalier Universitaire de Nice· Source
Not yet recruiting
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Recruiting
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source
Recruiting
PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.
2024-519753-11-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source
Not yet recruiting
Link Between ASCorbemia Level and Osteoporosis
NCT07660484· Centre Hospitalier Universitaire de Nice· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002· Phase 2/3· AbbVie· Source
Recruiting
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
NCT07647510· Phase 3· Dianthus Therapeutics· Source
Recruiting
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NCT07284602· Phase 3· PureTech· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Hoffmann-La Roche· Source
Recruiting
Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study
NCT07616687· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source
Recruiting
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
NCT07189325· Phase 3· University Hospital, Montpellier· Source
Recruiting
Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)
NCT07570589· Centre Hospitalier Universitaire de Nice· Source
Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source
Not yet recruiting
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source
Not yet recruiting
ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
2025-524728-22-01· Phase 1/2· Assistance Publique Hopitaux De Paris· Source
Not yet recruiting
Tdose Binding and Tocilizumab
NCT07582185· Phase 4· Centre Hospitalier Universitaire de Nice· Source
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521· Phase 3· UCB Biopharma SRL· Source
Recruiting
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

Showing 50 of 453.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00· Phase 3· Gilead Sciences Inc.· Source
Terminated
Presence of Anti-RACH Antibodies and Neurocognitive Disorder in Myasthenic or Alzheimers's Patients.
NCT06523296· Centre Hospitalier Universitaire de Nice· Source
Completed
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis
NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Completed
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)
NCT06984328· Phase 2· Genmab A/S· Source
Active, not recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source
Completed
A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of BP1.4979 in adult patients with essential tremor
2024-517987-46-00· Phase 2· Bioprojet Pharma· Source
Completed
A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis
NCT06867094· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Completed
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
NCT07225829· Phase 2· 4Moving Biotech· Source
Completed
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.
NCT06637631· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Completed
Impact of Individual Radiosensitivity on Late Toxicities of Radiosurgery in Essential Trigeminal Neuralgia
NCT06863324· Centre Hospitalier Universitaire de Nice· Source
Completed
A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML
NCT06563804· Phase 1/2· Institut De Recherches Internationales Servier IRIS· Source
Active, not recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920· Phase 3· Novartis Pharmaceuticals· Source
Withdrawn
Towards Optimal Screening and Management of Coronary Artery Disease in Diabetes: TOSCANA Study
NCT05314140· French Cardiology Society· Source
Completed
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.
NCT06447506· Phase 2· Glaxosmithkline Research & Development Limited· Source
Completed
ALS Phase II Study of NX210c
NCT06365216· Phase 2· Axoltis Pharma· Source
Recruiting
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
2023-504358-36-00· Phase 3· Sanofi-Aventis Recherche & Developpement· Source
Completed
Oral Azacitidine Maintenance Post-CPX 351
NCT06349239· Centre Hospitalier Universitaire de Nice· Source
Completed
Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
NCT06482437· Phase 2· NMD Pharma A/S· Source
Active, not recruiting
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027· Phase 3· Cerevance· Source
Active, not recruiting
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
NCT06243458· Phase 2· GCP-Service International West GmbH· Source
Completed
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303· Phase 2· Boehringer Ingelheim· Source
Completed
Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease
2023-507892-23-00· Phase 2· NMD Pharma A/S· Source
Completed
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419· Phase 2· AstraZeneca· Source
Active, not recruiting
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758· Phase 3· Novartis Pharmaceuticals· Source
Completed
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source
Active, not recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580· Phase 3· Vor Biopharma· Source
Completed
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
NCT06465186· Phase 2· Merck Sharp & Dohme LLC· Source
Terminated
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
NCT06444451· Phase 2· Sanofi· Source
Completed
Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF
NCT06468527· Phase 2· Kors van der Ent· Source
Completed
A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects with Cystic Fibrosis Aged 18 Years or Older (CHOICES)
2022-500410-26-01· Phase 2· University Medical Center Utrecht· Source
Completed
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis
2023-506655-19-00· Phase 2· Genentech Inc.· Source
Terminated
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
NCT06241573· Phase 2/3· Boehringer Ingelheim· Source
Completed
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE
NCT06079190· Phase 2· Glaxosmithkline Research & Development Limited· Source
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067· Phase 3· Erasca, Inc.· Source
Active, not recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552· Phase 3· argenx· Source
Withdrawn
Meaningful Aspects of Health for Adults With Dementia, Their Care Partners and Healthcare Practitioners
NCT06242574· Centre Hospitalier Universitaire de Nice· Source
Completed
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in Adult Participants with Moderate to Severe Atopic Dermatitis
NCT05999799· Phase 2· Glaxosmithkline Research & Development Limited· Source
Completed
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928· Phase 2· H. Lundbeck A/S· Source
Completed
Latent Tuberculosis Infection Screening Using QuantiFERON at Pre-Employment Assessment in Hospital Workers CHu Nice
NCT07608601· Centre Hospitalier Universitaire de Nice· Source
Active, not recruiting
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875· Phase 2· AbbVie· Source
Completed
Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven
NCT06030089· Centre Hospitalier Universitaire de Nice· Source
Active, not recruiting
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
NCT06282159· Phase 2· Dianthus Therapeutics· Source
Terminated
Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma
NCT04702854· Centre Hospitalier Universitaire de Nice· Source
Completed
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
NCT06280391· Phase 2· Sanofi· Source
Completed
Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease
NCT06080399· University Hospital, Toulouse· Source
Completed
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis
2022-502997-18-00· Phase 1· Bristol-Myers Squibb Services Unlimited Company· Source
Completed
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
2024-516672-16-00· Phase 3· Ab Science· Source
Completed
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)
2023-505910-10-00· Phase 2· Ryvu Therapeutics S.A.· Source
Completed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
NCT06224348· Phase 3· Sanofi· Source
Completed
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526· Phase 3· GB002, Inc.· Source

Showing 50 of 185.

Registry name variants (16)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Centre Hospitalier Universitaire de Nice
Nice, 06000
485 trials
CHU de Nice
Nice, 06000
110 trials
CHU Nice
Nice, 06000
36 trials
Nice - CHU
Nice, 06000
3 trials
- NCT06377579OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
  Contact: Thomas Cluzeau, Prof
- NCT06053099A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
  Contact: Jonathan BENZAQUEN
- NCT06808581EVALUATION OF SERUM INFLAMMATORY CYTOKINE CONCENTRATION IN HEREDITARY SENSITIVOMOTOR NEUROPATHIES
Centre Hospitalier Universitaire de Nice, Department of Neurosurgery
Nice
1 trial
- NCT02394626Surgery for Recurrent Glioblastoma
  Contact: Fabien Almairac
CENTRE HOSPITALIER UNIVERSITAIRE NICE - Service de Neurologie
Nice, 06000
1 trial
- NCT06155942Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes
  Contact: Cosmin Alecu, MD
CHU de Nice - Service de chirurgie vasculaire
Nice
1 trial
- NCT02728817Evaluation of the Radial Artery Deviation And Reimplantation Technique for Primary Hemodialysis Access Creation
CHU de Nice - service de neurologie
Nice
1 trial
- NCT05209815Safety of Exposure to Natalizumab During Pregnancy
CHU Nice (Expert center)
Nice, 06000
1 trial
- NCT03453268Impact of Reducing Antihypertensive Treatment on Mortality in Frail Subjects With Low Systolic Blood Pressure (SBP).
CHU NICE - Service de Néphrologie
Nice, 06002
1 trial
- NCT02154815Pre-emptive Kidney Transplantation Quality of Life
Nice CHU - Lenval
Nice
1 trial
- NCT02377245Juvenile Inflammatory Rheumatism (JIR) Cohorte
Service de rhumatologie - CHU de Nice
Nice
1 trial
- NCT02469753Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes
Centre Hospitalier Universitaire Nice
Nice, 06202
CHU de Nice - L'Archet
Nice, France 6202
CHU de Nice - service de rhumatologie
Nice
CHU de Nice - Service d'oncologie hématologie pédiatrique
Nice

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 05qsjq305 (CC0-1.0)Updated 12 Nov 2026

Report an error

Under construction, not live – Centre Hospitalier Universitaire de Nice: trials and research groups – Frontlight Research